furosemide has been researched along with Hearing Loss in 29 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ototoxic hearing loss was induced by intravenous administration of cisplatin, gentamicin, and furosemide." | 8.12 | Intratympanic Administration of Dieckol Prevents Ototoxic Hearing Loss. ( Li, H; Oh, SH; Shin, HC; Suh, MW, 2022) |
| "To reduce bilateral delayed-onset progressive sensory permanent hearing loss using a systems-wide quality improvement project with adherence to best practice for the administration of furosemide." | 7.91 | Avoiding Furosemide Ototoxicity Associated With Single-Ventricle Repair in Young Infants. ( Bond, GY; Bork, KT; Dinu, IA; Garcia Guerra, G; Hendson, L; Joffe, AR; Khodayari Moez, E; Rebeyka, IM; Robertson, CMT; Tawfik, G, 2019) |
| "Ototoxicity was produced by the combinations of a constant dose of AMI (500 mg/kg; i." | 5.91 | N-Acetyl-L-cysteine Affects Ototoxicity Evoked by Amikacin and Furosemide Either Alone or in Combination in a Mouse Model of Hearing Threshold Decrease. ( Szymański, M; Zadrożniak, M; Łuszczki, JJ, 2023) |
| "Children with hearing loss had lower birth weight for gestational age, more severe neonatal illness, with increased exposure to inotrope, steroid, gentamicin, vancomycin and furosemide, and more frequent physiological risk, elevated bilirubin and creatinine levels and acidosis, but no index child was found to have the m." | 4.31 | Cumulative risk factors contributing to hearing loss in preterm infants. ( Bitner-Glindzicz, M; Chant, K; Marlow, N, 2023) |
| " Ototoxic hearing loss was induced by intravenous administration of cisplatin, gentamicin, and furosemide." | 4.12 | Intratympanic Administration of Dieckol Prevents Ototoxic Hearing Loss. ( Li, H; Oh, SH; Shin, HC; Suh, MW, 2022) |
| "To reduce bilateral delayed-onset progressive sensory permanent hearing loss using a systems-wide quality improvement project with adherence to best practice for the administration of furosemide." | 3.91 | Avoiding Furosemide Ototoxicity Associated With Single-Ventricle Repair in Young Infants. ( Bond, GY; Bork, KT; Dinu, IA; Garcia Guerra, G; Hendson, L; Joffe, AR; Khodayari Moez, E; Rebeyka, IM; Robertson, CMT; Tawfik, G, 2019) |
| "At very high doses, furosemide is linked to ototoxicity in adults, but little is known about the risk of hearing loss in premature infants exposed to furosemide." | 3.88 | Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants. ( Balevic, S; Benjamin, DK; Clark, RH; Goldberg, RN; Greenberg, RG; Ku, LC; Laughon, M; Smith, PB; Wang, LA; Zimmerman, KO, 2018) |
| "Eligible participants included 54,721 female nurses aged 48 to 73 years in 1994 who provided information on thiazide diuretic and furosemide use in 1994, answered the question on hearing loss over their lifetime in 2012, and did not report hearing loss with date of onset before date of onset of hypertension diagnosis or medication use." | 3.83 | Hypertension, Diuretic Use, and Risk of Hearing Loss. ( Curhan, GC; Curhan, SG; Eavey, R; Lin, BM; Stankovic, KM; Wang, M, 2016) |
| " Here we present a case of a 77-year old man initiated on a sildenfil regimen for the treatment of pulmonary hypertension, who developed sudden bilateral hearing loss after taking sildenafil, in the setting of high dose furosemide and diltiazem." | 3.79 | Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance. ( Farquhar, D; Kim, RB; Mehta, S; Skeith, L; Yamashita, C, 2013) |
| "Kanamycin (500 mg/kg) and furosemide (50 mg/kg) were given to the healthy adult guinea pigs intramuscularly and intravenously to establish the deafness model." | 3.79 | [Math1 gene therapy for kanamycin and furosemide-induced deaf guinea pigs]. ( Gao, J; Guo, WW; Han, DY; Li, Z; Sun, AL; Sun, DX; Sun, JH; Wei, XN; Yang, SM; Zhang, XF, 2013) |
| "Systemic administration of kanamycin and furosemide induced profound hearing loss and severe hair cell damage." | 3.75 | Direct drug application to the round window: a comparative study of ototoxicity in rats. ( Camarero, G; García-Alcántara, F; Murillo-Cuesta, S; Rivera, T; Sistiaga, JA; Vacas, E; Varela-Nieto, I, 2009) |
| " The pathophysiology, clinical manifestations and risk factors and risk minimisation strategies regarding the ototoxicity associated with these drugs are presented in order to highlight this problem and reduce the incidence of adverse outcomes." | 2.43 | Systemic ototoxicity: a review. ( Coates, H; Shine, NP, 2005) |
| "Ototoxicity was produced by the combinations of a constant dose of AMI (500 mg/kg; i." | 1.91 | N-Acetyl-L-cysteine Affects Ototoxicity Evoked by Amikacin and Furosemide Either Alone or in Combination in a Mouse Model of Hearing Threshold Decrease. ( Szymański, M; Zadrożniak, M; Łuszczki, JJ, 2023) |
| "All VLBW infants examined for hearing impairment were included and data were retrieved retrospectively and analyzed for neonatal risk factors using logistic regression." | 1.46 | Prevalence and independent risk factors for hearing impairment among very low birth weight infants. ( Chiang, MC; Chu, SM; Fu, RH; Hsu, JF; Lien, R; Wang, CH; Yang, CY, 2017) |
| " Severe leukopenia (WBC < 2000/cu mm) and thrombocytopenia (< 100,000/cu mm) occurred in 25% and 45% of evaluable courses, respectively and necessitated dosage reduction in all and delay of therapy in some patients." | 1.26 | Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms. ( Bachur, NR; Chang, P; Egorin, MJ; Hahn, D; Klein, M; Leroy, A; Markus, S; Ostrow, S; Wiernik, PH, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (13.79) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 15 (51.72) | 24.3611 |
| 2020's | 4 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H | 1 |
| Oh, SH | 1 |
| Shin, HC | 1 |
| Suh, MW | 1 |
| Chant, K | 1 |
| Bitner-Glindzicz, M | 1 |
| Marlow, N | 1 |
| Zadrożniak, M | 1 |
| Szymański, M | 1 |
| Łuszczki, JJ | 1 |
| Lin, X | 1 |
| Li, G | 1 |
| Zhang, Y | 1 |
| Zhao, J | 1 |
| Lu, J | 1 |
| Gao, Y | 1 |
| Liu, H | 1 |
| Li, GL | 1 |
| Yang, T | 1 |
| Song, L | 1 |
| Wu, H | 1 |
| Deng, X | 2 |
| Hu, Z | 2 |
| García-Alcántara, F | 2 |
| Murillo-Cuesta, S | 2 |
| Pulido, S | 1 |
| Bermúdez-Muñoz, JM | 1 |
| Martínez-Vega, R | 1 |
| Milo, M | 1 |
| Varela-Nieto, I | 2 |
| Rivera, T | 2 |
| Wang, LA | 1 |
| Smith, PB | 1 |
| Laughon, M | 1 |
| Goldberg, RN | 1 |
| Ku, LC | 1 |
| Zimmerman, KO | 1 |
| Balevic, S | 1 |
| Clark, RH | 1 |
| Benjamin, DK | 1 |
| Greenberg, RG | 1 |
| Tian, K | 1 |
| Song, Y | 1 |
| Zhou, K | 1 |
| Yue, B | 1 |
| Qiu, Y | 1 |
| Sun, F | 1 |
| Wang, R | 1 |
| Zha, D | 1 |
| Qiu, J | 1 |
| Robertson, CMT | 1 |
| Bork, KT | 1 |
| Tawfik, G | 1 |
| Bond, GY | 1 |
| Hendson, L | 1 |
| Dinu, IA | 1 |
| Khodayari Moez, E | 1 |
| Rebeyka, IM | 1 |
| Garcia Guerra, G | 1 |
| Joffe, AR | 1 |
| Liu, Z | 1 |
| Li, X | 1 |
| Zhou, Y | 1 |
| Youm, I | 1 |
| Youan, BB | 1 |
| Skeith, L | 1 |
| Yamashita, C | 1 |
| Mehta, S | 1 |
| Farquhar, D | 1 |
| Kim, RB | 1 |
| Zhang, XF | 1 |
| Yang, SM | 1 |
| Han, DY | 1 |
| Guo, WW | 1 |
| Sun, JH | 1 |
| Gao, J | 1 |
| Sun, DX | 1 |
| Sun, AL | 1 |
| Li, Z | 2 |
| Wei, XN | 1 |
| Lin, BM | 1 |
| Curhan, SG | 1 |
| Wang, M | 1 |
| Eavey, R | 1 |
| Stankovic, KM | 1 |
| Curhan, GC | 1 |
| Clemens, E | 1 |
| de Vries, AC | 1 |
| Pluijm, SF | 1 |
| Am Zehnhoff-Dinnesen, A | 1 |
| Tissing, WJ | 1 |
| Loonen, JJ | 1 |
| van Dulmen-den Broeder, E | 1 |
| Bresters, D | 1 |
| Versluys, B | 1 |
| Kremer, LC | 1 |
| van der Pal, HJ | 1 |
| van Grotel, M | 1 |
| van den Heuvel-Eibrink, MM | 1 |
| Wang, CH | 1 |
| Yang, CY | 1 |
| Lien, R | 1 |
| Chu, SM | 1 |
| Hsu, JF | 1 |
| Fu, RH | 1 |
| Chiang, MC | 1 |
| Vacas, E | 1 |
| Sistiaga, JA | 1 |
| Camarero, G | 1 |
| Havenith, S | 1 |
| Versnel, H | 1 |
| Agterberg, MJ | 1 |
| de Groot, JC | 1 |
| Sedee, RJ | 1 |
| Grolman, W | 1 |
| Klis, SF | 1 |
| Hirose, K | 1 |
| Sato, E | 1 |
| Xiong, H | 1 |
| Chu, H | 1 |
| Zhou, X | 1 |
| Huang, X | 1 |
| Cui, Y | 1 |
| Zhou, L | 1 |
| Chen, J | 1 |
| Li, J | 1 |
| Wang, Y | 1 |
| Chen, Q | 1 |
| Shine, NP | 1 |
| Coates, H | 1 |
| Liu, HY | 1 |
| Chi, FL | 1 |
| Gao, WY | 1 |
| Ostrow, S | 1 |
| Egorin, MJ | 1 |
| Hahn, D | 1 |
| Markus, S | 1 |
| Leroy, A | 1 |
| Chang, P | 1 |
| Klein, M | 1 |
| Bachur, NR | 1 |
| Wiernik, PH | 1 |
| Aso, S | 1 |
| Watanabe, Y | 1 |
| Liu, JX | 1 |
| Zhou, XN | 1 |
| Yuan, YG | 1 |
| Alam, SA | 1 |
| Ikeda, K | 1 |
| Kawase, T | 1 |
| Kikuchi, T | 1 |
| Katori, Y | 1 |
| Watanabe, K | 1 |
| Takasaka, T | 1 |
| Gallagher, KL | 1 |
| Jones, JK | 1 |
| Futaki, T | 1 |
| Semba, T | 1 |
| Kudo, Y | 1 |
| Minami, Y | 1 |
| Nemoto, S | 1 |
1 review available for furosemide and Hearing Loss
| Article | Year |
|---|---|
Systemic ototoxicity: a review.
Topics: Africa South of the Sahara; Aminoglycosides; Antimalarials; Diuretics; Drug-Related Side Effects and | 2005 |
28 other studies available for furosemide and Hearing Loss
| Article | Year |
|---|---|
Intratympanic Administration of Dieckol Prevents Ototoxic Hearing Loss.
Topics: Animals; Cisplatin; Furosemide; Gentamicins; Hearing Loss; Hyaluronic Acid; Rats | 2022 |
Cumulative risk factors contributing to hearing loss in preterm infants.
Topics: Case-Control Studies; Child; Deafness; Furosemide; Gentamicins; Hearing Loss; Humans; Infant; Infant | 2023 |
N-Acetyl-L-cysteine Affects Ototoxicity Evoked by Amikacin and Furosemide Either Alone or in Combination in a Mouse Model of Hearing Threshold Decrease.
Topics: Acetylcysteine; Amikacin; Aminoglycosides; Animals; Anti-Bacterial Agents; Auditory Threshold; Deafn | 2023 |
Hearing consequences in Gjb2 knock-in mice: implications for human p.V37I mutation.
Topics: Animals; Asian People; Connexin 26; Connexins; Furosemide; Gene Expression Regulation; Gene Knock-In | 2019 |
Generation of Cochlear Hair Cells from Sox2 Positive Supporting Cells via DNA Demethylation.
Topics: Animals; Azacitidine; DNA Methylation; Female; Furosemide; Hair Cells, Auditory; Hearing Loss; Kanam | 2020 |
The expression of oxidative stress response genes is modulated by a combination of resveratrol and N-acetylcysteine to ameliorate ototoxicity in the rat cochlea.
Topics: Acetylcysteine; Animals; Antioxidants; Apoptosis; Auditory Fatigue; Brain Stem; Cochlea; Cytoprotect | 2018 |
Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants.
Topics: Bronchopulmonary Dysplasia; Diuretics; Evoked Potentials, Auditory, Brain Stem; Female; Furosemide; | 2018 |
Upregulation of HSP60 expression in the postnatal rat cochlea and rats with drug-induced hearing loss.
Topics: Animals; Auditory Threshold; Chaperonin 60; Cochlea; Evoked Potentials, Auditory, Brain Stem; Furose | 2018 |
Avoiding Furosemide Ototoxicity Associated With Single-Ventricle Repair in Young Infants.
Topics: Cardiopulmonary Resuscitation; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Furose | 2019 |
Generation of new hair cells by DNA methyltransferase (Dnmt) inhibitor 5-azacytidine in a chemically-deafened mouse model.
Topics: Animals; Azacitidine; Cochlea; Disease Models, Animal; DNA (Cytosine-5-)-Methyltransferase 1; Ear, I | 2019 |
Uptake mechanism of furosemide-loaded pegylated nanoparticles by cochlear cell lines.
Topics: Animals; Cell Death; Cell Line; Cell Survival; Cochlea; Drug Carriers; Drug Delivery Systems; Endocy | 2013 |
Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance.
Topics: Aged; Canada; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Diuretics; Dose- | 2013 |
[Math1 gene therapy for kanamycin and furosemide-induced deaf guinea pigs].
Topics: Adenoviridae; Animals; Basic Helix-Loop-Helix Transcription Factors; Cochlea; Deafness; Ear, Inner; | 2013 |
Hypertension, Diuretic Use, and Risk of Hearing Loss.
Topics: Aged; Female; Furosemide; Hearing Loss; Humans; Hypertension; Middle Aged; Prospective Studies; Risk | 2016 |
Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Audiometry, Pure-Tone; Carboplatin; Child; Ch | 2016 |
Prevalence and independent risk factors for hearing impairment among very low birth weight infants.
Topics: Anti-Bacterial Agents; Craniofacial Abnormalities; Diuretics; Ductus Arteriosus, Patent; Evoked Pote | 2017 |
Direct drug application to the round window: a comparative study of ototoxicity in rats.
Topics: Administration, Topical; Animals; Cochlea; Evoked Potentials, Auditory, Brain Stem; Furosemide; Hear | 2009 |
Spiral ganglion cell survival after round window membrane application of brain-derived neurotrophic factor using gelfoam as carrier.
Topics: Acoustic Stimulation; Animals; Auditory Threshold; Brain-Derived Neurotrophic Factor; Cell Shape; Ce | 2011 |
Comparative analysis of combination kanamycin-furosemide versus kanamycin alone in the mouse cochlea.
Topics: Acoustic Stimulation; Animals; Atrophy; Auditory Threshold; Cell Death; Cell Movement; Cochlea; Dise | 2011 |
Conservation of endocochlear potential in mice with profound hearing loss induced by co-administration of kanamycin and furosemide.
Topics: Animals; Anti-Bacterial Agents; Auditory Threshold; Cell Death; Cell Survival; Cochlea; Cochlear Mic | 2011 |
Taurine attenuates aminoglycoside ototoxicity by inhibiting inducible nitric oxide synthase expression in the cochlea.
Topics: Aminoglycosides; Animals; Cochlea; Disease Models, Animal; Down-Regulation; Drug Interactions; Evoke | 2008 |
Cis-Dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms.
Topics: Adolescent; Adult; Aged; Blood Platelet Disorders; Cisplatin; Doxorubicin; Drug Administration Sched | 1980 |
Electrocochleography in the diagnosis of delayed endolymphatic hydrops.
Topics: Action Potentials; Adolescent; Adult; Aged; Aged, 80 and over; Audiometry, Evoked Response; Child; D | 1994 |
Effects of furosemide on intracochlear oxygen tension in the guinea pig.
Topics: Animals; Cochlea; Diuretics; Dose-Response Relationship, Drug; Evoked Potentials, Auditory; Female; | 1996 |
Acute effects of combined administration of kanamycin and furosemide on the stria vascularis studied by distortion product otoacoustic emission and transmission electron microscopy.
Topics: Animals; Anti-Bacterial Agents; Diuretics; Drug Synergism; Furosemide; Guinea Pigs; Hearing Loss; Ka | 1998 |
Furosemide-induced ototoxicity.
Topics: Adolescent; Adult; Aged; Aminoglycosides; Ethacrynic Acid; Female; Furosemide; Hearing Loss; Humans; | 1979 |
Treatment of hydropic patients by immunoglobulin with methyl B12.
Topics: Adult; Aged; Combined Modality Therapy; Drug Resistance; Edema; Endolymphatic Sac; Female; Furosemid | 1988 |
[A case of hearing loss presumably induced by furosemide].
Topics: Aged; Audiometry; Female; Furosemide; Hearing Loss; Hearing Loss, Bilateral; Heart Diseases; Humans | 1985 |